EGFR and lung adenocarcinoma: The in vivo efficacy of Orlistat was further examined in the transgenic CCSP‐rTTA‐EGFR L858R‐T790M‐driven lung adenocarcinoma mouse model (Politi et al, 2006; Li et al, 2007).